Navigation Links
PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
Date:4/28/2009

ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it will be hosting a conference call for investors on Wednesday, April 29th beginning at 4:30 p.m. E.T., to review the status of its rPA anthrax vaccine program.

The dial-in number within the United States is 866-788-0540. The dial-in number for international callers is 857-350-1678. The participant passcode is 82129094.

A replay of the conference call will be available for 30 days, beginning at approximately 7:30 p.m. Eastern Time on Wednesday, April 29, 2009 until approximately 11:59 p.m. Eastern Time on May 29, 2009. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 53903666.

The conference call will also be webcast and can be accessed from the company's website at www.pharmathene.com. A link to the webcast may be found on the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatm
    '/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
2. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
3. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
4. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
5. MedNet Solutions to Share Industry Expertise at the 13th Annual EDC & Beyond Conference in Orlando, FL
6. Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference
7. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
8. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
9. NewCardio Leadership to Present Two Abstracts at ISCE Conference
10. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
11. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 17, 2014  Hanger, Inc. (NYSE: HGR ... results of operations for the quarter ended September 30, ... closes.  A conference call to discuss these results is ... November 7, 2014. Those wishing to participate should call ... 14, 2014 by dialing 1-855-859-2056 and referencing Conference ID ...
(Date:10/17/2014)... October 17, 2014 ... has announced the addition of the  "China ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... in China impacted ... in consumption concept, dietary habit, way of ...
(Date:10/17/2014)... DUBLIN , October 17, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has ... Market Monitor : North American Automated ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The ... forecast, 2008-2018 analyzes the market of ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2
... Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication ... June 9 A new analysis demonstrated that ... severely active rheumatoid arthritis (RA) who had prior ... received subcutaneous injections of SIMPONI(TM) (golimumab) once every ...
... in June Issue of Circulation , , SILVER ... Corporation (Nasdaq: UTHR ) and Eli Lilly ... the results of a pivotal 16-week study showing that ... improved exercise capacity and improved time to clinical worsening ...
Cached Medicine Technology:New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 3New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 4New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 5New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 6New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 7New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 8New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 9New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 10Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 2Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 3Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 4Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 5Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily 6
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... Based on a proprietary chromatid-specific ... assays capable of determining DNA sequence, location and ... three dimensions of high-resolution data, dGH assays are ... range of disease-causing genetic rearrangements, including chromosomal inversions ... tools, including today’s advanced sequencing technologies. , According ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... to be introduced in the U.S., has a lot to ... time when our country recognizes the achievements and contributions of ... marks the anniversary for Punzoné, and today it shares its ... and take a trip to Italy - even if it ...
(Date:10/19/2014)... 20, 2014 Recently, BambooIndustry.com, one of ... its new range of bamboo deckings . Moreover, ... natural items; they are now available at deeply discounted ... it is hard to overstate the significance of online ... to online services. The company’s workers are striving to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many kinds ... designs of 2014 mother of the bride dresses ... offered with big discounts, up to 70% off. All ... enjoy this special offer. , Owing to the ... one of the leading brands in the global market. ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... , ... medical founder of Minute Clinic, joins Consult A Doctor, Inc. as Chief Medical Officer; calls ... , ... 13, 2010 -- Consult A Doctor, Inc . announced today that Douglas Smith, board-certified ...
... ... Journal of Otology and Neurotology a “Letter to the Editor” documenting the improvement for ... Prosthesis Syndrome” focuses on two recent cases that were referred to Dr. Lippy, following ... ...
... ... ... Music announces the April 13, 2010 release of , in my room , -a ... and produced by LML recording artist D.C. Anderson , the prolific writer/producer/performer behind the ...
... ... mobile networks will rise to almost $1.9 billion globally by 2014, with heart based monitoring ... ... According to Juniper Research, revenues from remote patient monitoring using mobile networks will rise to ...
... ... , ... (Vocus) April 13, 2010 -- Susan Z. Robins, President of Muscle Angels™, launched ... The response was overwhelmingly positive and Muscle Angel Massagers™ were awarded a “Top ...
... , HOUSTON - The molecular machinery that switches on a ... other organs has been identified by an international team led ... Cancer Center. The paper was published Sunday in Nature ... a target-rich environment for development of drugs to thwart expression ...
Cached Medicine News:Health News:Consult A Doctor, Inc. Names Retail Clinic Pioneer, Douglas Smith, M.D. as Chief Medical Officer 2Health News:Consult A Doctor, Inc. Names Retail Clinic Pioneer, Douglas Smith, M.D. as Chief Medical Officer 3Health News:New Study Identifies Cause of Severe Disequilibrium and Significant Memory Loss Following Stapedectomy Surgery 2Health News:Peter Bradley Adams, Victoria Shaw, Many Distinguished Colleagues Ally To Benefit National MS Society With CD Release: In My Room 2Health News:Peter Bradley Adams, Victoria Shaw, Many Distinguished Colleagues Ally To Benefit National MS Society With CD Release: In My Room 3Health News:Peter Bradley Adams, Victoria Shaw, Many Distinguished Colleagues Ally To Benefit National MS Society With CD Release: In My Room 4Health News:Revenues from Mobile Health Monitoring to Reach $1.9 Billion Globally by 2014 Says Juniper Research 2Health News:Revenues from Mobile Health Monitoring to Reach $1.9 Billion Globally by 2014 Says Juniper Research 3Health News:Muscle Angel Massagers™ Receive Accolades from Dentists and Hygienists 2Health News:Muscle Angel Massagers™ Receive Accolades from Dentists and Hygienists 3Health News:Muscle Angel Massagers™ Receive Accolades from Dentists and Hygienists 4Health News:Muscle Angel Massagers™ Receive Accolades from Dentists and Hygienists 5Health News:Scientists find key to gene that promotes cancer metastasis 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0540....
Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
Antigenic Total Protein S, ELISA Method...
Medicine Products: